2007
DOI: 10.1016/j.bbrc.2006.12.199
|View full text |Cite
|
Sign up to set email alerts
|

Antipsychotics inhibit TREK but not TRAAK channels

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
37
0

Year Published

2010
2010
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 50 publications
(42 citation statements)
references
References 26 publications
5
37
0
Order By: Relevance
“…Accordingly, it has been proposed that the clinical usefulness of SSRI antidepressants is complemented by the inhibition of TREK-1 channels (133, 317). This suggests that the blockers of this background K ϩ channel are of considerable therapeutic interest for the future management of psychiatric diseases (223,224,317). TREK-1 and TREK-2 (but not TRAAK) channels are also inhibited by several neuroleptic drugs, such as chlorpromazine (269), fluphenazine, haloperidol, and penfluridol (317).…”
Section: Depression and Selective Serotonin Reuptake Inhibitorsmentioning
confidence: 99%
See 1 more Smart Citation
“…Accordingly, it has been proposed that the clinical usefulness of SSRI antidepressants is complemented by the inhibition of TREK-1 channels (133, 317). This suggests that the blockers of this background K ϩ channel are of considerable therapeutic interest for the future management of psychiatric diseases (223,224,317). TREK-1 and TREK-2 (but not TRAAK) channels are also inhibited by several neuroleptic drugs, such as chlorpromazine (269), fluphenazine, haloperidol, and penfluridol (317).…”
Section: Depression and Selective Serotonin Reuptake Inhibitorsmentioning
confidence: 99%
“…This suggests that the blockers of this background K ϩ channel are of considerable therapeutic interest for the future management of psychiatric diseases (223,224,317). TREK-1 and TREK-2 (but not TRAAK) channels are also inhibited by several neuroleptic drugs, such as chlorpromazine (269), fluphenazine, haloperidol, and penfluridol (317). Further studies are needed to evaluate the significance of this effect in the therapeutic potential of neuroleptics.…”
Section: Depression and Selective Serotonin Reuptake Inhibitorsmentioning
confidence: 99%
“…Moreover, TRAAK-family K2P channels are modulated by cellular lipids and pharmacological agents, including polyunsaturated fatty acids such as arachidonic acid and volatile general anesthetics [42] . Acidity and heat have also been suggested to activate the channel [43,44] , while antipsychotics such as fluphenazine have been shown to block TREK-1 but not the related TRAAK channels [45] .…”
Section: Traak-family Channelsmentioning
confidence: 99%
“…[9][10][11] It has also been reported that paroxetine inhibits the G proteinactivated inwardly rectifying K + channel 12) and two P domain background K + channel, TREK. 13) These results suggest that paroxetine may have an effect on the cardiovascular system. However, the side effects of paroxetine on the cardiovascular system have not been thoroughly studied.…”
mentioning
confidence: 90%